Tingke Xie , Yanyan Lan , Chengming Chen , Jing Han
{"title":"Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis","authors":"Tingke Xie , Yanyan Lan , Chengming Chen , Jing Han","doi":"10.1016/j.prmcm.2025.100598","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of combining anti-VEGF and fufang xueshuangtong in the treatment of wet age-related macular degeneration (wet AMD).</div></div><div><h3>Methods</h3><div>A systematic review of studies focusing on the efficacy and safety of the combined anti-VEGF and Fufang Xueshuantong therapy versus anti-VEGF monotherapy for wet AMD was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42024593135). The outcomes were reported as weighted mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.</div></div><div><h3>Results</h3><div>A total of 9 studies, involving 731 participants, were included. The MD for best-corrected visual acuity (BCVA) improvement, central macular thickness (CMT), and size of choroidal neovascularization (CNV) between the combination therapy and monotherapy groups were 7.37 (95 % CI [5.35 to 9.39]), −35.57 (95 % CI [−47.02 to −24.12]), and −1.81 (95 % CI [−2.56 to −1.07]), respectively. Additionally, the combination therapy group showed greater improvement in serum and ocular hemodynamics and had a lesser impact on intraocular pressure, and there was no significant difference in the incidence of adverse reactions between the two regimens.</div></div><div><h3>Conclusions</h3><div>The combination of anti-VEGF therapy with Fufang Xueshuantong provides superior efficacy compared to anti-VEGF monotherapy in the treatment of wet AMD and is associated with an improved safety profile. However, further trials are needed to enhance the robustness and reliability of these findings.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100598"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Modern Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667142525000272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
To evaluate the effectiveness and safety of combining anti-VEGF and fufang xueshuangtong in the treatment of wet age-related macular degeneration (wet AMD).
Methods
A systematic review of studies focusing on the efficacy and safety of the combined anti-VEGF and Fufang Xueshuantong therapy versus anti-VEGF monotherapy for wet AMD was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42024593135). The outcomes were reported as weighted mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.
Results
A total of 9 studies, involving 731 participants, were included. The MD for best-corrected visual acuity (BCVA) improvement, central macular thickness (CMT), and size of choroidal neovascularization (CNV) between the combination therapy and monotherapy groups were 7.37 (95 % CI [5.35 to 9.39]), −35.57 (95 % CI [−47.02 to −24.12]), and −1.81 (95 % CI [−2.56 to −1.07]), respectively. Additionally, the combination therapy group showed greater improvement in serum and ocular hemodynamics and had a lesser impact on intraocular pressure, and there was no significant difference in the incidence of adverse reactions between the two regimens.
Conclusions
The combination of anti-VEGF therapy with Fufang Xueshuantong provides superior efficacy compared to anti-VEGF monotherapy in the treatment of wet AMD and is associated with an improved safety profile. However, further trials are needed to enhance the robustness and reliability of these findings.